Outcomes of Patellar Subchondroplasty Surgery: A Case Series.


Journal

The journal of knee surgery
ISSN: 1938-2480
Titre abrégé: J Knee Surg
Pays: Germany
ID NLM: 101137599

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 26 6 2023
pubmed: 29 7 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

A select subset of patients can present with anterior knee pain in the setting of normal patellar tracking, no significant cartilage damage, and the presence of a bone marrow lesion (BML) involving the patella on advanced imaging. One novel treatment option for this condition is patellar subchondroplasty, where calcium phosphate is injected into the subchondral bone under fluoroscopic guidance. The purpose of this study is to report preliminary outcomes of patients who have undergone subchondroplasty of the patella. The surgical log of the senior author was retrospectively reviewed to identify patients who had undergone patellar subchondroplasty from January 2014 to June 2019. Indications for surgery included the presence of retropatellar pain refractory to conservative management without significant arthritis with a related focal BML on magnetic resonance imaging. International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome Score (KOOS), and Veterans Rand 12-item Health Survey (VR-12) were obtained preoperatively, at 6 months and at final follow-up. Eight patients (nine knees) who underwent patellar subchondroplasty with minimum 1-year follow-up participated in the study. On preoperative magnetic resonance imaging, patients had a mean BML that was 2 cm in diameter. Patients had a median Kellgren-Lawrence grade of 2 both preoperatively and at final radiographic follow-up (15.50 ± 20.52 months). No patient underwent subsequent surgery or conversion to arthroplasty. Compared with baseline, VR-12 mental (

Identifiants

pubmed: 35901796
doi: 10.1055/s-0042-1747944
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

941-948

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

W.M.C. reports Medical Device Business Services Inc. $2100—(2019). S.E.W. reports the following disclosures:

Auteurs

Hailey P Huddleston (HP)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

William M Cregar (WM)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

Mohamad M Alzein (MM)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

Amar S Vadhera (AS)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

Stephanie E Wong (SE)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

Adam B Yanke (AB)

Department of Orthopaedics, Rush University Medical Center, Chicago, Illinois.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH